24/7 Market News Snapshot 01 July, 2025 – Vivos Therapeutics, Inc. Common Stock (NASDAQ:VVOS)

July 1, 2025

DENVER, Colo., 01 July, 2025 (www.247marketnews.com) – (NASDAQ:VVOS) are discussed in this article.
Vivos Therapeutics, Inc. (NASDAQ:VVOS), recognized for its pioneering role in medical technology aimed at addressing obstructive sleep apnea (OSA) and snoring, is experiencing a significant upward surge in its stock price. The company is currently trading at $6.11, marking an impressive 93.35% rise from a previous close of $3.16, with a trading volume reaching 8.10 million shares. This bullish momentum reflects strong investor confidence and excitement about the company’s latest developments.

A key driver of this enthusiasm is the recent approval by the Centers for Medicare & Medicaid Services (CMS) for Vivos Therapeutics’ VidaSleep™ oral appliance, which incorporates innovative Unilateral Bite Block technology. This approval allows for the treatment of mild to moderate OSA in adults, thereby greatly enhancing patient access to cutting-edge solutions. Given that over 80% of OSA cases in the United States remain undiagnosed, affecting around 80 million individuals, the introduction of Medicare coverage for VidaSleep™ represents a pivotal advancement. This development is expected to encourage more commercial insurers to adopt similar coverage policies, broadening Vivos’ market reach.

Kirk Huntsman, CEO and Chairman of Vivos Therapeutics, emphasized that this milestone reinforces the company’s strategy within the value-based care sector of the sleep apnea market. The dual-device portfolio, including VidaSleep™ and Vivos mmRNA®, allows clinicians to provide tailored, effective treatments while ensuring robust profit margins. Designed for both standalone use and as an adjunct to traditional CPAP therapy, VidaSleep™ stands as a testament to Vivos’ commitment to delivering high-quality solutions aimed at improving clinical outcomes and addressing the root causes of OSA.

With increasing awareness of the implications of OSA, Vivos Therapeutics is strategically positioned to lead the charge in transforming the landscape of sleep health, reflecting its dedication to innovating within a rapidly evolving market.

Related news for (VVOS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.